These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 12384373)

  • 1. Stampidine is a potent inhibitor of Zidovudine- and nucleoside analog reverse transcriptase inhibitor-resistant primary clinical human immunodeficiency virus type 1 isolates with thymidine analog mutations.
    Uckun FM; Pendergrass S; Venkatachalam TK; Qazi S; Richman D
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3613-6. PubMed ID: 12384373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of stampidine against primary clinical human immunodeficiency virus isolates.
    Uckun FM; Pendergrass S; Qazi S; Venkatachalam TK
    Arzneimittelforschung; 2004; 54(1):69-77. PubMed ID: 14979612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potency of stampidine against multi-nucleoside reverse transcriptase inhibitor resistant human immunodeficiency viruses.
    Uckun FM; Venkatachalam TK; Qazi S
    Arzneimittelforschung; 2006 Feb; 56(2A):193-203. PubMed ID: 16570827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stampidine as a novel nucleoside reverse transcriptase inhibit with potent anti-HIV activity.
    Uckun FM
    Arzneimittelforschung; 2006 Feb; 56(2A):121-35. PubMed ID: 16570821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo toxicity, pharmacokinetics, and anti-human immunodeficiency virus activity of stavudine-5'-(p-bromophenyl methoxyalaninyl phosphate) (stampidine) in mice.
    Uckun FM; Qazi S; Pendergrass S; Lisowski E; Waurzyniak B; Chen CL; Venkatachalam TK
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3428-36. PubMed ID: 12384347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-retroviral activity of GMP-grade stampidine against genotypically and phenotypically nucleoside reverse transcriptase inhibitor resistant recombinant human immunodeficiency virus. An in vitro study.
    Uckun FM; DuMez D; Qazi S; Tibbles H; Venkatachalam TK
    Arzneimittelforschung; 2007; 57(2):112-21. PubMed ID: 17396622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro anti-HIV potency of stampidine alone and in combination with standard anti-HIV drugs.
    Uckun FM; Qazi S; Venkatachalam TK
    Arzneimittelforschung; 2005; 55(4):223-31. PubMed ID: 15901046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stampidine as a promising antiretroviral drug candidate for pre-exposure prophylaxis against sexually transmitted HIV/AIDS.
    Uckun FM; Cahn P; Qazi S; D'Cruz O
    Expert Opin Investig Drugs; 2012 Apr; 21(4):489-500. PubMed ID: 22360744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unmet challenges in HIV therapy and potential of stampidine.
    Uckun FM
    Arzneimittelforschung; 2006 Feb; 56(2A):117-20. PubMed ID: 16570820
    [No Abstract]   [Full Text] [Related]  

  • 10. Thymidine-analog and multi-nucleoside resistance mutations are observed in both zidovudine-naive and zidovudine-experienced subjects with viremia after treatment with stavudine-containing regimens.
    Ross L; Henry K; Paar D; Salvato P; Shaefer M; Fisher R; Liao Q; St Clair M
    J Hum Virol; 2001; 4(4):217-22. PubMed ID: 11694850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of purified recombinant reverse transcriptase from wild-type and zidovudine-resistant clinical isolates of human immunodeficiency virus type 1 by zidovudine, stavudine, and lamivudine triphosphates.
    Duan C; Poticha D; Stoeckli TC; Petropoulos CJ; Whitcomb JM; McHenry CS; Kuritzkes DR
    J Infect Dis; 2001 Nov; 184(10):1336-40. PubMed ID: 11679926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A structural frame for understanding the role of thymidine analogue resistance mutations in resistance to zidovudine and other nucleoside analogues.
    Menéndez-Arias L
    Antivir Ther; 2011; 16(7):943-6. PubMed ID: 22024508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1.
    Smith RA; Raugi DN; Wu VH; Leong SS; Parker KM; Oakes MK; Sow PS; Ba S; Seydi M; Gottlieb GS;
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7437-46. PubMed ID: 26392486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens.
    Ross L; Scarsella A; Raffanti S; Henry K; Becker S; Fisher R; Liao Q; Hirani A; Graham N; St Clair M; Hernandez J;
    AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1107-15. PubMed ID: 11522180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2'-deoxynucleoside triphosphates.
    Meyer PR; Matsuura SE; Schinazi RF; So AG; Scott WA
    Antimicrob Agents Chemother; 2000 Dec; 44(12):3465-72. PubMed ID: 11083661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, separation and anti-HIV activity of distereoisomers of N-[p-(4-bromophenyl) -2',3'-didehydro-3'-deoxy-5'-thymidylyl]-L-alanine methyl ester (stampidine).
    Venkatachalam TK; Qazi S; Uckun FM
    Arzneimittelforschung; 2006 Feb; 56(2A):152-8. PubMed ID: 16570823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and evaluation of a thermoreversible ovule formulation of stampidine, a novel nonspermicidal broad-spectrum anti-human immunodeficiency virus microbicide.
    D'Cruz OJ; Samuel P; Waurzyniak B; Uckun FM
    Biol Reprod; 2003 Dec; 69(6):1843-51. PubMed ID: 12890726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations.
    Miranda LR; Götte M; Liang F; Kuritzkes DR
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2648-56. PubMed ID: 15980332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine.
    Ait-Khaled M; Stone C; Amphlett G; Clotet B; Staszewski S; Katlama C; Tisdale M;
    AIDS; 2002 Aug; 16(12):1686-9. PubMed ID: 12172093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypic resistance pattern of HIV-1 isolates with zidovudine and/or multidrug resistance mutations after didanosine-stavudine combination therapy.
    Pellegrin I; Segondy M; Garrigue I; Izopet J; Montes B; Pellegrin JL; Reynes J; Massip P; Puel J; Fleury H
    J Acquir Immune Defic Syndr; 2000 Dec; 25(5):465-6. PubMed ID: 11141248
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.